Neuraltus Pharmaceuticals Announces Last Patient Out for ALS Study

Neuraltus’ Phase I ALS clinical trial of NP001 therapy has closed. This novel small molecule drug is thought to confer neuroprotection by dampening the immunological response seen in ALS pathology.

Click here to read more.

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail